Please login to the form below

Not currently logged in
Email:
Password:

Neurimmune appoints chief business officer

Fabian Buller will further drive the biopharma’s growth strategy

Monoclonal antibody-focused Neurimmune has appointed Fabian Buller into the newly created role of chief business officer.

Buller joins the biopharmaceutical group’s executive team, bringing with him eight years of biotech and pharma experience.

Prior to joining Neurimmune, Buller served as director new ventures at Johnson & Johnson Innovation, as well as director of business development of Covagen.

Roger Nitsch, president and CEO of Neurimmune, said: “We are pleased that Dr Buller joins our company to further drive our growth strategy.

“Dr Buller has an impressive track record in business development and licensing transactions.

“He will play a key role in realising opportunities that will allow us to bring novel therapeutics to patients.”

2nd May 2018

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics